GYRE compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

GYREGyre Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

GYREGyre Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

GYRE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±65.8%▲+4.22%×0.06

May 7 '26±42.3%▼−12.06%×0.29

Q1 FY26±56.7%▼−6.30%×0.11

Q3 FY25±71.0%▼−1.77%×0.03

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedGYRE realized, solidLLY realized, hatchedOne scale, both sides: full bar = 71%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

GYREGyre Therapeutics, Inc.

4.58▲+14.21%

Mkt cap$447.2MRevenue$33MQ3 FY26Revenue$120MFY25

LLYELI Lilly & Co

1,353.87▼−0.80%

Regular sessionNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Regular sessionNov 6 '26

GYREGyre Therapeutics, Inc.

LLYELI Lilly & Co

4.58▲+14.21%

Price

1,353.87▼−0.80%

$447.2M

Mkt cap

$1.2T

Q3 FY26$33M

Revenue

$24.4BQ3 FY26

FY25$120M

Revenue

$65.2BFY25

GYRE4.58▲+14.21%vsLLY1,353.87▼−0.80%Regular sessionNov 6 '26